Skip to content
FrontierPicks

Watching

INSM · Insmed

Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin

Event-driven Catalyst · M&A & special situations

Note written ·

The last three months

Up 14.0% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.

INSM daily closes from 24 August 2026 to 20 November 2026, last $141.33, with its price line set under the older rule: a daily close below $119.80; 50-day average $111.09 on 20 November 2026. 24 August 2026: $123.98; 50-day average $111.3425 August 2026: $123.89; 50-day average $111.8726 August 2026: $124.39; 50-day average $112.4027 August 2026: $121.39; 50-day average $112.9228 August 2026: $118.54; 50-day average $113.3231 August 2026: $121.82; 50-day average $113.841 September 2026: $121.51; 50-day average $114.302 September 2026: $126.63; 50-day average $114.793 September 2026: $126.68; 50-day average $115.264 September 2026: $126.29; 50-day average $115.698 September 2026: $124.89; 50-day average $116.129 September 2026: $128.80; 50-day average $116.6010 September 2026: $127.28; 50-day average $117.0211 September 2026: $129.41; 50-day average $117.4614 September 2026: $125.30; 50-day average $117.7415 September 2026: $119.92; 50-day average $117.9116 September 2026: $122.58; 50-day average $118.1017 September 2026: $123.98; 50-day average $118.2518 September 2026: $120.00; 50-day average $118.2821 September 2026: $121.00; 50-day average $118.3922 September 2026: $120.82; 50-day average $118.6323 September 2026: $118.34; 50-day average $118.7924 September 2026: $121.55; 50-day average $119.0325 September 2026: $117.83; 50-day average $119.2328 September 2026: $117.67; 50-day average $119.4229 September 2026: $115.63; 50-day average $119.5930 September 2026: $114.14; 50-day average $119.701 October 2026: $108.59; 50-day average $119.742 October 2026: $111.12; 50-day average $119.825 October 2026: $103.83; 50-day average $119.756 October 2026: $105.23; 50-day average $119.767 October 2026: $101.74; 50-day average $119.728 October 2026: $100.48; 50-day average $119.669 October 2026: $100.60; 50-day average $119.6512 October 2026: $98.56; 50-day average $119.6413 October 2026: $96.79; 50-day average $119.6114 October 2026: $97.79; 50-day average $119.5915 October 2026: $99.21; 50-day average $119.6016 October 2026: $96.27; 50-day average $118.8719 October 2026: $95.29; 50-day average $118.1520 October 2026: $95.67; 50-day average $117.3721 October 2026: $94.04; 50-day average $116.6022 October 2026: $95.06; 50-day average $115.8623 October 2026: $93.39; 50-day average $115.2026 October 2026: $93.33; 50-day average $114.5927 October 2026: $94.96; 50-day average $113.9228 October 2026: $96.98; 50-day average $113.2929 October 2026: $111.59; 50-day average $112.9130 October 2026: $112.58; 50-day average $112.662 November 2026: $109.31; 50-day average $112.333 November 2026: $104.44; 50-day average $111.944 November 2026: $110.00; 50-day average $111.665 November 2026: $108.76; 50-day average $111.356 November 2026: $114.41; 50-day average $111.219 November 2026: $116.10; 50-day average $111.1610 November 2026: $119.49; 50-day average $111.1211 November 2026: $120.75; 50-day average $111.1012 November 2026: $118.07; 50-day average $110.9313 November 2026: $121.16; 50-day average $110.8216 November 2026: $122.88; 50-day average $110.7517 November 2026: $121.86; 50-day average $110.6918 November 2026: $119.80; 50-day average $110.5119 November 2026: $144.46; 50-day average $110.8620 November 2026: $141.33; 50-day average $111.09

Daily closes, to . Red: the note's price line under the older rule, a daily close below $119.80, set on 20 November 2026. The pale line is the 50-day average, $111.09 on .

Price line

A daily close below $119.80, the 18 November 2026 close before the Sanofi report, which would show the takeover premium gone. An FDA rejection of the Arikayce label expansion on 28 January 2027 would also show the case failing.

A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.

Research onlyNot in the portfolio.

The portfolio's record →

The business · as of

Insmed sells two drugs for serious lung diseases. Brinsupri treats non-cystic fibrosis bronchiectasis. Arikayce treats MAC lung infection. Both are sold in the US, Europe and Japan. Revenue was $524.4 million in the quarter to 30 September 2026, of which Brinsupri brought in $400.1 million.

What is changing, and what follows · as of

What is changing now
On 19 November 2026 Bloomberg reported that Sanofi is weighing a takeover of Insmed and speaking with advisers. The shares closed at $144.46, up from $119.80 the session before.
What follows for the company
Brinsupri sales lifted gross margin to 85.1% and cut the operating loss to $89.4 million in the third quarter of 2026. Research spending of $270.0 million still kept four-quarter free cash flow at −$628 million.
What follows for its customers, suppliers and competitors
A bid would give Sanofi (SNY) a respiratory drug launch as Dupixent patents near expiry, and Bloomberg said other suitors could emerge. TPIP targets markets United Therapeutics (UTHR) serves with Tyvaso.

What the price assumes · as of

At the 19 November 2026 close (filed inputs to 29 October 2026) the shares trade at 20.5 times sales and 43.6 times book value, for an enterprise value of $31,092 million. EV/EBIT and P/E are not meaningful because the company still loses money. That holds only if revenue keeps compounding from the latest quarter's $524 million while the −17.0% operating margin turns positive.

Key figures from the filings · Health Care

Quarter to 30 September 2026, filed 29 October 2026; valuation at the 20 November 2026 close

The last six quarters

Revenue, its change on a year and gross margin over the six quarters to 30 September 2026, from the company's filings with the SEC, the latest filed 29 October 2026. Operating margin is not drawn: in at least one quarter it is below −100%, beyond the chart's scale. All filed numbers, below, lists every quarter.
Revenue, latest quarter ($M)
524
Revenue, change on a year (%)
+268.4
Gross margin (%)
85.1
Operating margin (%)
−17.0
Free cash flow, four quarters ($M)
−628
Net cash, cash less debt ($M)
600
Enterprise value to sales (×)
20.0
Free-cash-flow yield (%)
−2.0
All filed numbers

What Insmed reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Results by quarter Each quarter with the day its figures were first filed, and the day of a later filing that changed them
Quarter to Revenue ($M) On a year (%) Gross margin (%) Operating margin (%)
first filed 524 +268.4 85.1 −17.0
first filed 426 +296.1 84.2 −0.4
first filed 306 +229.6 84.5 −50.1
first filed 264 +152.6 83.2 −121.2
first filed 142 +52.4 79.4 −257.1
first filed 107 +18.9 73.9 −291.3
Income Quarter to 30 September 2026, filed 29 October 2026
Pre-tax income ($M) −97.7
Net income ($M) four quarters: −606 −100
Diluted shares, change on a year (%) against the quarter to 30 September 2025 +3.3
Cash flow Four quarters to 30 September 2026, filed 29 October 2026
Operating cash flow ($M) −596
Capital spending ($M) 32.0
Free cash flow ($M) −628
Balance sheet At 30 September 2026, filed 29 October 2026
Cash and short-term investments ($M) 1,147
Debt ($M) long-term debt 547
Net cash, cash less debt ($M) 600
Deferred revenue ($M) Not reported
Backlog, orders not yet delivered ($M) Not reported
Receivables ($M) 259
Inventory ($M) 164
Shareholders' equity ($M) 726
Valuation At the 20 November 2026 close, filed figures to 29 October 2026
Market value ($M) 31,005
Enterprise value, market value plus net debt ($M) 30,405
Enterprise value to sales (×) 20.0
Enterprise value to operating income (×) Not meaningful
Price to earnings (×) Not meaningful
Price to book value (×) 42.7
Free-cash-flow yield (%) −2.0

Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 6.4% of shares outstanding sold short, 3.6 days of average trading to cover, +4.5% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date
Window Bought Sold
90 days Not available yet Not available yet
12 months Not available yet Not available yet

Linked companies · as of

Competitors:
UTHR

The thesis

Insmed's shares are more likely than not to beat the S&P 500 over the next three months. Two things support that view. Bloomberg reported on 19 November 2026 that Sanofi is weighing a takeover. Separately, the company's lung-disease drug Brinsupri sold $400.1 million in its third full quarter on the market. The Food and Drug Administration (FDA) decision on the Arikayce label expansion, due 28 January 2027, is the next dated test. Whether Sanofi makes a bid is the other.

The rating is Medium. The takeover report puts a floor of interest under the shares, and the launch numbers give a buyer a reason to pay. It is not High because no offer exists. Reuters reported on 19 November 2026 that neither company commented and that any deal "could still be weeks away." Without a bid, the gain from the report can unwind.

Bullish and bearish views on Insmed Incorporated

The bull case on Insmed Incorporated (INSM), in brief: Brinsupri launch is ahead of plan. The bear case: the premium rests on an unconfirmed report.

Bull case

  • Brinsupri launch is ahead of plan. Brinsupri revenue was $400.1 million in the quarter to 30 September 2026, up 29% from $309.2 million in the previous quarter. Total revenue was $524.4 million, up 268% from a year earlier (company 8-K, 29 October 2026).
  • Guidance floor moved up. On 29 October 2026 the company raised the low end of its 2026 Brinsupri revenue guidance to $1.35–1.4 billion, from $1.25–1.4 billion. It raised Arikayce guidance to $460–470 million, from $450–470 million.
  • A strategic buyer is circling. Bloomberg reported on 19 November 2026 that Sanofi is speaking with advisers about a takeover. The same report said other suitors could emerge. Sanofi's chief executive has called business development "critical" ahead of Dupixent patent expiries in the early 2030s.
  • Margins are moving the right way. Gross margin rose to 85.1% in the quarter to 30 September 2026, from 79.4% a year earlier. The operating margin improved to −17.0%, from −257.1% (10-Q filed 29 October 2026).
  • A near-term regulatory event. The FDA accepted the Arikayce supplemental application for all patients with MAC lung disease under Priority Review. The decision date is 28 January 2027 (company 8-K, 29 October 2026). MAC is Mycobacterium avium complex, a hard-to-treat lung infection.

Bear case

  • The premium rests on an unconfirmed report. The 19 November 2026 move came from a Bloomberg report citing people familiar with the matter. Neither company commented to Reuters that day. If Sanofi steps back, the report-day gain could unwind.
  • Still losing money and burning cash. The net loss was $100.3 million in the quarter to 30 September 2026. Free cash flow was −$628 million over the four quarters to that date. Cash and short-term investments were $1,147 million against $547 million of long-term debt (10-Q filed 29 October 2026).
  • Heavy spending on the next drug. Research and development expense rose to $270.0 million in the third quarter of 2026, from $186.4 million a year earlier. The pipeline includes three TPIP Phase 3 programs. PALM-ILD enrollment is not expected to finish until the first half of 2028 (company 8-K, 29 October 2026).
  • Earnings missed the consensus. The third-quarter 2026 loss of $0.46 a share was wider than the Zacks consensus loss of $0.34 (Zacks, 29 October 2026).
  • A director sold before the rally. Director David R. Brennan sold 25,000 shares in the open market at $124.00 on 9 September 2026 (SEC Form 4, filed 11 September 2026).

Price setup · as of

The shares closed at $144.46 on 19 November 2026, up from $119.80 on 18 November 2026, on the day of the Sanofi report. The price had held between $118.07 and $122.88 from 12 November to 18 November 2026. The 19 November 2026 close is above the 50-day moving average of $110.86 and the 200-day moving average of $122.61, both as of that close.

The 3-month price change is 14.9%, against a reference close of $125.77 on 21 August 2026. The shares are still 32.1% below the 52-week intraday high of $212.75, set on 2 December 2025. The 52-week closing low was $91.88 on 10 June 2026. The pre-report closes from $118 to $123 mark where the price traded before takeover interest became public. A return to that range would mean the market no longer expects a bid.

Across liquid US stocks, no reliable effect has been found so far for what a one-day jump of this size means for the following 21 or 63 sessions.

Catalysts ahead

  • 28 January 2027: FDA decision date on the Arikayce supplemental application for all MAC lung disease patients. Approval would widen Arikayce's US market and support the case. A rejection would weaken both the drug's growth and a buyer's valuation.
  • ~19 February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether full-year Brinsupri revenue lands within the $1.35–1.4 billion guidance, and whether the operating loss keeps narrowing.

What would change the view

The risks this note tracks, each with what would confirm it:

  • Sanofi decides not to bid and the takeover premium leaves the shares. Confirmed by: a statement from Sanofi or Insmed, or a follow-up report from Bloomberg or Reuters, saying talks have ended or that no approach is under way.
  • Brinsupri growth slows as the launch matures. Confirmed by: fourth-quarter 2026 Brinsupri revenue that puts the full year below the $1.35 billion low end of guidance.
  • The FDA does not approve the wider Arikayce label. Confirmed by: a complete response letter, or a delay announced on or before the 28 January 2027 decision date.
  • Cash burn forces new share sales, diluting holders. Confirmed by: an equity or convertible offering. Diluted shares were already up 3.3% from a year earlier in the quarter to 30 September 2026.

What it trades with · as of

For now the shares are trading on the deal. Their next big move depends on news from Sanofi (SNY), or a denial, more than on the biotech group. Brinsupri sales and the FDA decision on 28 January 2027 drive the company-specific path.

TPIP, Insmed's inhaled treprostinil, is aimed at markets United Therapeutics (UTHR) serves with Tyvaso. Trial news in pulmonary hypertension moves both names. Single stocks vary widely: the standard deviation of 63-session returns across liquid US stocks was 27% in 2026, so a three-month result for one name is a noisy reading.

Caveats

  • Insmed is not yet profitable: its net loss was $100.3 million in the quarter to 30 September 2026, and free cash flow was negative over the four quarters to that date. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (8)
  1. Third-quarter 2026 revenue was $524.4 million, up 268% from $142.3 million a year earlier. Brinsupri contributed $400.1 million and Arikayce $124.4 million. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
  2. Insmed raised its 2026 Brinsupri revenue guidance to $1.35–1.4 billion, from $1.25–1.4 billion. It raised Arikayce guidance to $460–470 million, from $450–470 million. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
  3. The FDA accepted the Arikayce supplemental application for all MAC lung disease patients under Priority Review, with a decision date of 28 January 2027. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of
  4. Bloomberg reported that Sanofi is weighing a takeover of Insmed and speaking with advisers. Neither company immediately commented to Reuters. Reuters via Yahoo News, 19 November 2026 · as of
  5. The third-quarter 2026 net loss was $100.3 million, or $0.46 a share. The Zacks consensus loss was $0.34 a share. Zacks, 29 October 2026; Insmed 8-K, 29 October 2026 · as of
  6. Cash and short-term investments were $1,147 million against $547 million of long-term debt at 30 September 2026. Insmed 10-Q for the third quarter of 2026 · as of
  7. Director David R. Brennan sold 25,000 shares in the open market at $124.00 on 9 September 2026. SEC Form 4 filed 11 September 2026 · as of
  8. Brinsupri was approved in Japan in August 2026 for non-cystic fibrosis bronchiectasis and launched there in October 2026. Insmed 8-K, exhibit 99.1, 29 October 2026 · as of

Sources

Related · shared themes

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X